1
IRUS TotalDownloads
Altmetric
An omics-based machine learning approach to predict diabetes progression: a RHAPSODY study
File | Description | Size | Format | |
---|---|---|---|---|
s00125-024-06105-8.pdf | Published version | 1.06 MB | Adobe PDF | View/Open |
Title: | An omics-based machine learning approach to predict diabetes progression: a RHAPSODY study |
Authors: | Slieker, RC Münch, M Donnelly, LA Bouland, GA Dragan, I Kuznetsov, D Elders, PJM Rutter, GA Ibberson, M Pearson, ER 't Hart, LM Van de Wiel, MA Beulens, JWJ |
Item Type: | Journal Article |
Abstract: | Aims/hypothesis People with type 2 diabetes are heterogeneous in their disease trajectory, with some progressing more quickly to insulin initiation than others. Although classical biomarkers such as age, HbA1c and diabetes duration are associated with glycaemic progression, it is unclear how well such variables predict insulin initiation or requirement and whether newly identified markers have added predictive value. Methods In two prospective cohort studies as part of IMI-RHAPSODY, we investigated whether clinical variables and three types of molecular markers (metabolites, lipids, proteins) can predict time to insulin requirement using different machine learning approaches (lasso, ridge, GRridge, random forest). Clinical variables included age, sex, HbA1c, HDL-cholesterol and C-peptide. Models were run with unpenalised clinical variables (i.e. always included in the model without weights) or penalised clinical variables, or without clinical variables. Model development was performed in one cohort and the model was applied in a second cohort. Model performance was evaluated using Harrel’s C statistic. Results Of the 585 individuals from the Hoorn Diabetes Care System (DCS) cohort, 69 required insulin during follow-up (1.0–11.4 years); of the 571 individuals in the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) cohort, 175 required insulin during follow-up (0.3–11.8 years). Overall, the clinical variables and proteins were selected in the different models most often, followed by the metabolites. The most frequently selected clinical variables were HbA1c (18 of the 36 models, 50%), age (15 models, 41.2%) and C-peptide (15 models, 41.2%). Base models (age, sex, BMI, HbA1c) including only clinical variables performed moderately in both the DCS discovery cohort (C statistic 0.71 [95% CI 0.64, 0.79]) and the GoDARTS replication cohort (C 0.71 [95% CI 0.69, 0.75]). A more extensive model including HDL-cholesterol and C-peptide performed better in both cohorts (DCS, C 0.74 [95% CI 0.67, 0.81]; GoDARTS, C 0.73 [95% CI 0.69, 0.77]). Two proteins, lactadherin and proto-oncogene tyrosine-protein kinase receptor, were most consistently selected and slightly improved model performance. Conclusions/interpretation Using machine learning approaches, we show that insulin requirement risk can be modestly well predicted by predominantly clinical variables. Inclusion of molecular markers improves the prognostic performance beyond that of clinical variables by up to 5%. Such prognostic models could be useful for identifying people with diabetes at high risk of progressing quickly to treatment intensification. Data availability Summary statistics of lipidomic, proteomic and metabolomic data are available from a Shiny dashboard at https://rhapdata-app.vital-it.ch. |
Issue Date: | May-2024 |
Date of Acceptance: | 5-Jan-2024 |
URI: | http://hdl.handle.net/10044/1/111195 |
DOI: | 10.1007/s00125-024-06105-8 |
ISSN: | 0012-186X |
Publisher: | Springer |
Start Page: | 885 |
End Page: | 894 |
Journal / Book Title: | Diabetologia |
Volume: | 67 |
Issue: | 5 |
Copyright Statement: | © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
Publication Status: | Published |
Conference Place: | Germany |
Online Publication Date: | 2024-02-19 |
Appears in Collections: | Department of Medicine (up to 2019) Faculty of Medicine |
This item is licensed under a Creative Commons License